MedTrace Logo

(ACTH) for the Treatment of Sarcoid Uveitis

NCT03473964 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2018-03-22

No results posted yet for this study

Summary

Sarcoidosis is a multisystem granulomatous disease that can affect nearly any organ in the body. While most commonly affecting the lungs, vision threatening eye involvement occurs in approximately 25% of patients with sarcoid. Eye involvement may lead to a chronic, sight-threatening uveitis which may result in cataract, glaucoma, and macular edema. The treatment of sarcoid uveitis involves the use of topical and systemic corticosteroids or potent immunosuppressive agents (medications that suppress the body's immune system) both of which can cause severe long-term side effects. The adverse effects of steroids may be avoided by treatment with the use as H.P. Acthar® Gel. The effectiveness of H.P. Acthar® Gel in the treatment of sarcoid uveitis and patient quality of live have not been previously examined. These issues, will be explored in this research.

Conditions

  • Sarcoid Uveitis

Interventions

DRUG

H.P. Acthar gel

H.P. Acthar gel: Injection 40 mg twice weekly

Sponsors & Collaborators

  • John Huang, MD

    lead OTHER

Principal Investigators

  • John J Huang, MD · New England Retina Associates

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2019-03-31
Completion
2020-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03473964 on ClinicalTrials.gov